Ab­b­Vie’s patent-ag­gres­sive US strat­e­gy for flag­ship Hu­mi­ra pays off, as judge dis­miss­es law­suit al­leg­ing an­ti­com­pet­i­tive ac­tiv­i­ty

Ab­b­Vie has long fierce­ly pro­tect­ed its flag­ship Hu­mi­ra — the world’s best­selling drug — with a patent rain­coat per­haps as durable as a Mack­in­tosh. And while it has made a se­ries of moves for a post-Hu­mi­ra fu­ture, no­tably the $63 bil­lion ac­qui­si­tion of Al­ler­gan, a US judge has ruled in fa­vor of the com­pa­ny against al­le­ga­tions that it en­gaged in an­ti­com­pet­i­tive con­duct to el­bow out ri­vals in the Unit­ed States.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters